Weskamp P, Ufton D, Drysch M, Wagner J, Dadras M, Lehnhardt M
Cancers (Basel). 2022; 14(5).
PMID: 35267581
PMC: 8909240.
DOI: 10.3390/cancers14051273.
Wang C, Zhang S, Ma B, Fu Y, Luo Y
Oncogene. 2022; 41(16):2357-2371.
PMID: 35256783
DOI: 10.1038/s41388-022-02260-7.
Ghatak D, Ghosh D, Roychoudhury S
Front Oncol. 2021; 10:604124.
PMID: 33505918
PMC: 7830093.
DOI: 10.3389/fonc.2020.604124.
Di Agostino S, Fontemaggi G, Strano S, Blandino G, DOrazi G
J Exp Clin Cancer Res. 2019; 38(1):290.
PMID: 31277687
PMC: 6612074.
DOI: 10.1186/s13046-019-1302-0.
Meng X, Yang S, Li Y, Li Y, Devor E, Bi J
Dis Markers. 2019; 2018:3810108.
PMID: 30647797
PMC: 6311857.
DOI: 10.1155/2018/3810108.
A spontaneous model of spondyloarthropathies that develops bone loss and pathological bone formation: A process regulated by IL27RA-/- and mutant-p53.
Dibra D, Xia X, Gagea M, Lozano G, Li S
PLoS One. 2018; 13(3):e0193485.
PMID: 29494633
PMC: 5832250.
DOI: 10.1371/journal.pone.0193485.
Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.
Zhou R, Xu A, Gingold J, Strong L, Zhao R, Lee D
Trends Pharmacol Sci. 2017; 38(10):908-927.
PMID: 28818333
PMC: 5752137.
DOI: 10.1016/j.tips.2017.07.004.
Modulation of cell death in human colorectal and breast cancer cells through a manganese chelate by involving GSH with intracellular p53 status.
Banerjee K, Das S, Majumder S, Majumdar S, Biswas J, Choudhuri S
Mol Cell Biochem. 2016; 427(1-2):35-58.
PMID: 28012015
DOI: 10.1007/s11010-016-2896-6.
The downregulation of ΔNp63 in p53-deficient mouse epidermal tumors favors metastatic behavior.
Bornachea O, Lopez-Calderon F, Duenas M, Segrelles C, Lorz C, Suarez-Cabrera C
Oncotarget. 2015; 6(27):24230-45.
PMID: 26203771
PMC: 4695182.
DOI: 10.18632/oncotarget.4353.
Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.
Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y
Proc Natl Acad Sci U S A. 2014; 111(30):11145-50.
PMID: 25024203
PMC: 4121829.
DOI: 10.1073/pnas.1404139111.
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.
Eischen C, Lozano G
Hum Mutat. 2014; 35(6):728-37.
PMID: 24488925
PMC: 4725600.
DOI: 10.1002/humu.22524.
Mutant TP53 posttranslational modifications: challenges and opportunities.
Nguyen T, Menendez D, Resnick M, Anderson C
Hum Mutat. 2014; 35(6):738-55.
PMID: 24395704
PMC: 4074372.
DOI: 10.1002/humu.22506.
Correlation of transcription of MALAT-1, a novel noncoding RNA, with deregulated expression of tumor suppressor p53 in small DNA tumor virus models.
Jeffers L, Duan K, Ellies L, Seaman W, Burger-Calderon R, Diatchenko L
J Cancer Ther. 2013; 4(3).
PMID: 24163781
PMC: 3808111.
DOI: 10.4236/jct.2013.43094.
Functions of TAp63 and p53 in restraining the development of metastatic cancer.
Tan E, Morton J, Timpson P, Tucci P, Melino G, Flores E
Oncogene. 2013; 33(25):3325-33.
PMID: 23873029
PMC: 4181588.
DOI: 10.1038/onc.2013.287.
More targets, more pathways and more clues for mutant p53.
Garritano S, Inga A, Gemignani F, Landi S
Oncogenesis. 2013; 2:e54.
PMID: 23817466
PMC: 3740285.
DOI: 10.1038/oncsis.2013.15.
Gender, mutant p53 and PML: a growing "affaire" in tumor suppression and oncogenesis.
Di Agostino S, Strano S, Blandino G
Cell Cycle. 2013; 12(12):1824-5.
PMID: 23759566
PMC: 3735694.
DOI: 10.4161/cc.25174.
Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.
Wu R, Baker S, Hu T, Norman K, Fearon E, Cho K
Am J Pathol. 2013; 182(4):1391-9.
PMID: 23499052
PMC: 3620412.
DOI: 10.1016/j.ajpath.2012.12.031.
p53 mutations in cancer.
Muller P, Vousden K
Nat Cell Biol. 2012; 15(1):2-8.
PMID: 23263379
DOI: 10.1038/ncb2641.
Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
Li Q, Lozano G
Clin Cancer Res. 2012; 19(1):34-41.
PMID: 23262034
PMC: 3537867.
DOI: 10.1158/1078-0432.CCR-12-0053.
p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.
Chen L, Tweddle D
Front Oncol. 2012; 2:173.
PMID: 23226679
PMC: 3508619.
DOI: 10.3389/fonc.2012.00173.